Literature DB >> 23979744

Biological markers of Pseudomonas aeruginosa epidemic high-risk clones.

Xavier Mulet1, Gabriel Cabot, Alain A Ocampo-Sosa, M Angeles Domínguez, Laura Zamorano, Carlos Juan, Fe Tubau, Cristina Rodríguez, Bartolomé Moyà, Carmen Peña, Luis Martínez-Martínez, Antonio Oliver.   

Abstract

A limited number of Pseudomonas aeruginosa genotypes (mainly ST-111, ST-175, and ST-235), known as high-risk clones, are responsible for epidemics of nosocomial infections by multidrug-resistant (MDR) or extensively drug-resistant (XDR) strains worldwide. We explored the potential biological parameters that may explain the success of these clones. A total of 20 isolates from each of 4 resistance groups (XDR, MDR, ModR [resistant to 1 or 2 classes], and MultiS [susceptible to all antipseudomonals]), recovered from a multicenter study of P. aeruginosa bloodstream infections performed in 10 Spanish hospitals, were analyzed. A further set of 20 XDR isolates belonging to epidemic high-risk clones (ST-175 [n = 6], ST-111 [n = 7], and ST-235 [n = 7]) recovered from different geographical locations was also studied. When unknown, genotypes were documented through multilocus sequence typing. The biological parameters evaluated included twitching, swimming, and swarming motility, biofilm formation, production of pyoverdine and pyocyanin, spontaneous mutant frequencies, and the in vitro competition index (CI) obtained with a flow cytometry assay. All 20 (100%) XDR, 8 (40%) MDR, and 1 (5%) ModR bloodstream isolate from the multicenter study belonged to high-risk clones. No significant differences were observed between clonally diverse ModR and MultiS isolates for any of the parameters. In contrast, MDR/XDR high-risk clones showed significantly increased biofilm formation and mutant frequencies but significantly reduced motility (twitching, swimming, and swarming), production of pyoverdine and pyocyanin, and fitness. The defined biological markers of high-risk clones, which resemble those resulting from adaptation to chronic infections, could be useful for the design of specific treatment and infection control strategies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23979744      PMCID: PMC3811276          DOI: 10.1128/AAC.01481-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  51 in total

1.  Growing and analyzing static biofilms.

Authors:  Judith H Merritt; Daniel E Kadouri; George A O'Toole
Journal:  Curr Protoc Microbiol       Date:  2005-07

Review 2.  The surprisingly diverse ways that prokaryotes move.

Authors:  Ken F Jarrell; Mark J McBride
Journal:  Nat Rev Microbiol       Date:  2008-05-07       Impact factor: 60.633

3.  Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain.

Authors:  Esther Viedma; Carlos Juan; Joshi Acosta; Laura Zamorano; Joaquín R Otero; Francisca Sanz; Fernando Chaves; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2009-09-08       Impact factor: 5.191

Review 4.  Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium.

Authors:  N Mesaros; P Nordmann; P Plésiat; M Roussel-Delvallez; J Van Eldere; Y Glupczynski; Y Van Laethem; F Jacobs; P Lebecque; A Malfroot; P M Tulkens; F Van Bambeke
Journal:  Clin Microbiol Infect       Date:  2007-01-31       Impact factor: 8.067

5.  Chronic Pseudomonas aeruginosa infection in chronic obstructive pulmonary disease.

Authors:  Laura Martínez-Solano; María D Macia; Alicia Fajardo; Antonio Oliver; Jose L Martinez
Journal:  Clin Infect Dis       Date:  2008-12-15       Impact factor: 9.079

6.  Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation.

Authors:  A Mena; E E Smith; J L Burns; D P Speert; S M Moskowitz; J L Perez; A Oliver
Journal:  J Bacteriol       Date:  2008-10-10       Impact factor: 3.490

Review 7.  Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms.

Authors:  Philip D Lister; Daniel J Wolter; Nancy D Hanson
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

8.  Benefit of having multiple ampD genes for acquiring beta-lactam resistance without losing fitness and virulence in Pseudomonas aeruginosa.

Authors:  Bartolomé Moya; Carlos Juan; Sebastián Albertí; José L Pérez; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2008-07-21       Impact factor: 5.191

9.  Outbreak of Pseudomonas aeruginosa infections with PER-1 extended-spectrum beta-lactamase in Warsaw, Poland: further evidence for an international clonal complex.

Authors:  Joanna Empel; Krzysztof Filczak; Agnieszka Mrówka; Waleria Hryniewicz; David M Livermore; Marek Gniadkowski
Journal:  J Clin Microbiol       Date:  2007-07-18       Impact factor: 5.948

Review 10.  Regulation of virulence and antibiotic resistance by two-component regulatory systems in Pseudomonas aeruginosa.

Authors:  W James Gooderham; Robert E W Hancock
Journal:  FEMS Microbiol Rev       Date:  2009-03       Impact factor: 16.408

View more
  38 in total

1.  Evolution of Pseudomonas aeruginosa Antimicrobial Resistance and Fitness under Low and High Mutation Rates.

Authors:  Gabriel Cabot; Laura Zamorano; Bartolomé Moyà; Carlos Juan; Alfonso Navas; Jesús Blázquez; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2016-01-04       Impact factor: 5.191

2.  High-Resolution Analysis by Whole-Genome Sequencing of an International Lineage (Sequence Type 111) of Pseudomonas aeruginosa Associated with Metallo-Carbapenemases in the United Kingdom.

Authors:  Jane F Turton; Laura Wright; Anthony Underwood; Adam A Witney; Yuen-Ting Chan; Ali Al-Shahib; Catherine Arnold; Michel Doumith; Bharat Patel; Timothy D Planche; Jonathan Green; Richard Holliman; Neil Woodford
Journal:  J Clin Microbiol       Date:  2015-06-03       Impact factor: 5.948

3.  Determinants for persistence of Pseudomonas aeruginosa in hospitals: interplay between resistance, virulence and biofilm formation.

Authors:  S J Kaiser; N T Mutters; A DeRosa; C Ewers; U Frank; F Günther
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-10-12       Impact factor: 3.267

4.  Deciphering the Resistome of the Widespread Pseudomonas aeruginosa Sequence Type 175 International High-Risk Clone through Whole-Genome Sequencing.

Authors:  Gabriel Cabot; Carla López-Causapé; Alain A Ocampo-Sosa; Lea M Sommer; María Ángeles Domínguez; Laura Zamorano; Carlos Juan; Fe Tubau; Cristina Rodríguez; Bartolomé Moyà; Carmen Peña; Luis Martínez-Martínez; Patrick Plesiat; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

5.  Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC.

Authors:  Gabriel Cabot; Sebastian Bruchmann; Xavier Mulet; Laura Zamorano; Bartolomé Moyà; Carlos Juan; Susanne Haussler; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2014-03-17       Impact factor: 5.191

6.  Comparison of local features from two Spanish hospitals reveals common and specific traits at multiple levels of the molecular epidemiology of metallo-β-lactamase-producing Pseudomonas spp.

Authors:  Esther Viedma; Vanesa Estepa; Carlos Juan; Jane Castillo-Vera; Beatriz Rojo-Bezares; Cristina Seral; Francisco Javier Castillo; Yolanda Sáenz; Carmen Torres; Fernando Chaves; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2014-02-03       Impact factor: 5.191

7.  Infections in intensive care unit adult patients harboring multidrug-resistant Pseudomonas aeruginosa: implications for prevention and therapy.

Authors:  B Borgatta; L Lagunes; A T Imbiscuso; M N Larrosa; M Lujàn; J Rello
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-01-16       Impact factor: 3.267

8.  WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent "β-Lactam Enhancer" Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones.

Authors:  Bartolome Moya; Isabel M Barcelo; Sachin Bhagwat; Mahesh Patel; German Bou; Krisztina M Papp-Wallace; Robert A Bonomo; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

9.  Genomics and Susceptibility Profiles of Extensively Drug-Resistant Pseudomonas aeruginosa Isolates from Spain.

Authors:  Ester Del Barrio-Tofiño; Carla López-Causapé; Gabriel Cabot; Alba Rivera; Natividad Benito; Concepción Segura; María Milagro Montero; Luisa Sorlí; Fe Tubau; Silvia Gómez-Zorrilla; Nuria Tormo; Raquel Durá-Navarro; Esther Viedma; Elena Resino-Foz; Marta Fernández-Martínez; Claudia González-Rico; Izaskun Alejo-Cancho; Jose Antonio Martínez; Cristina Labayru-Echverria; Carlos Dueñas; Ignacio Ayestarán; Laura Zamorano; Luis Martinez-Martinez; Juan Pablo Horcajada; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

10.  Acute Inflammatory Response of Patients with Pseudomonas aeruginosa Infections: A Prospective Study.

Authors:  Silvia Gómez-Zorrilla; Francisco Morandeira; María José Castro; Fe Tubau; Elisabet Periche; Rosario Cañizares; María Angeles Dominguez; Javier Ariza; Carmen Peña
Journal:  Microb Drug Resist       Date:  2016-10-18       Impact factor: 3.431

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.